Published on December 17, 2009 at 12:44 AM
USACIG, Inc. and Hop-on, Inc. (PINKSHEETS: HPNN)
are proud to announce that USACIG has signed an exclusive agreement with
Hop-on, Inc. to submit its Electric Cigarette Nicotine water technology to
the FDA for clinical studies for the prevention of Parkinson's disease and
for the alleviation of its symptoms.
Peter Michaels, CEO of Hop-on, states, "Studies on nicotine through
cigarette use have proven to delay the onset of Parkinson's disease.
Nicotine in its natural state removed from cigarettes is safe and
non-toxic. USACIG nicotine water technology delivers pure organic and
non-toxic nicotine without harmful chemicals. While nicotine has had an
image problem due to its association with smoking, there is much excitement
about nicotine's potential to prevent and help with a number of medical
issues. We are very excited about being USACIG's exclusive agent for FDA
submission. USACIG will be working on the funding for clinical studies."
The Parkinson's Institute and Clinical Center is also continuing research
showing that intermittent nicotine treatment reduces medication-induced
dyskinesias by as much as 50% in models of Parkinson's disease. Lead by
senior research scientist, Maryka Quik, Ph.D.
SOURCE: USACIG, Inc.